Leah Kuntz

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.

Frank Clark, MD, the Psychiatric Times Diversity & Inclusion Section Editor, was recently appointed president of The Greenville County Medical Society, the first Black doctor to serve in this role.

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

This APSARD 2024 conference poster finds that individuals with ADHD have distinct motivations and patterns of substance use.

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

It is Transgender Awareness Week. Here’s what you need to know as a clinician.

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.

Just because a patient has anxiety or past trauma does not mean they cannot enjoy this spooky holiday…

Positive results were just released from 2 phase 3 clinical trials evaluating centanafadine for the treatment of adolescents and children with ADHD.

Michael F. Myers, MD provided tips and advice to clinicians who might be dealing with a patient contemplating suicide.

Tony Thrasher, DO, DFAPA, shared his thoughts on emergency psychiatry: an honor and a great stressor.

Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.

Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.

The FDA has released a draft guide to offer their perspective and thoughts on the development of treatments for stimulant use disorder.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.

The senior vice president of research at the American Foundation for Suicide Prevention offers thoughts on suicide and students.